Clinical trial

Mechanism of Antidepressant-Related Dysfunctional Arousal in High-Risk Youth

Name
DelBello/Singh AIM
Description
A 16-week double blind, placebo-controlled investigation of escitalopram in adolescents with depression and/or anxiety with a family history of Bipolar Disorder. Subjects will be evaluated using semi-structured diagnostic interviews and symptom ratings, participate in a MRI scan and then randomized to treatment. Following randomization, high-risk youth will have visits every week for the first 4 weeks of treatment then biweekly up to 16 weeks during which time tolerability and ratings will be performed. MRI scan will be repeated at week 4.
Trial arms
Trial start
2015-12-01
Estimated PCD
2022-07-01
Trial end
2022-12-01
Status
Completed
Treatment
Escitalopram
Youth in the MED condition will be given the USFDA approved antidepressant, escitalopram for the treatment of depression or anxiety in youth and follow a standard dose titration schedule of 5 mg/day for 1 week, 10mg/day for 1 week, then with a target dose of 20-30 mg/day by 4 weeks. Titration will be no faster than 5mg/week. This titration guideline was drawn from the escitalopram package insert for pediatric dosing, which states that target doses may be achieved by 4 weeks.
Arms:
MED - Escitalopram with psychotherapy
Other names:
Lexapro
Cognitive behavioral Psychotherapy
All participants (No MED and MED) will be assigned a study-trained therapist who will provide hour-long weekly individual cognitive behavioral psychotherapy (CBT) based on current evidence-based practices for the treatment of anxiety and depressive symptoms for youth.
Arms:
No MED -Psychotherapy
Other names:
CBT
Size
214
Primary endpoint
Baseline-endpoint change in prefrontal-amygdala functional connectivity by Scan.
Baseline to 16 weeks
Eligibility criteria
Inclusion Criteria: Inclusion - High-Risk Youth: 1. age 12 years, 0 mos. - 17 years, 11 mos.; 2. at least one parent or step-parent/guardian with whom the subject lives is willing to participate in research sessions; 3. the child and relative(s) are able and willing to give written informed assent/consent to participate, respectively; 4. the youth meets criteria for high-risk: * has at least one first degree relative with Bipolar I Disorder, as assessed by the Structured Clinical Interview for DSM (SCID; First et al. 1995), the Kiddie Schedule for Affective Disorders and Schizophrenia (KSADS-PL, Kaufman et al., 1997), and the Family History-Research Diagnostic Criteria (FH-RDC; Andreasen et al., 1977); * the youth shows evidence of current significant depressive or anxiety symptoms as determined by a current Childhood Depression Rating Scale-Revised (CDRS-R, Poznanski et al.,1984) score \> 35 and/or a current Pediatric Anxiety Rating Scale (PARS, 2002) score \> 15. Inclusion - Healthy Controls: 1. age 12 years, 0 mos. - 17 years, 11 mos.; 2. at least one parent or step-parent/guardian with whom the subject lives is willing to participate in research sessions; 3. the child and relative(s) are able and willing to give written informed assent/consent to participate, respectively; 4. no personal or family history of any psychopathology as assessed by the KSADS-PL structured clinical interview (Kaufman et al., 1997) and the Family History-Research Diagnostic Criteria (FH-RDC; Andreasen et al., 1977). Exclusion Criteria: Exclusion - High-Risk Youth \& Healthy Controls: 1. any history of syndromal bipolar I or II disorder (i.e., history of mania, mixed episode, or major depression with hypomania); 2. a history of previous antidepressant exposure 3. a DSM-5 diagnosis of autism, pervasive developmental disorder, OCD(Obsessive-Compulsive Disorder), PTSD, Tourette's disorder, or any psychotic disorder including schizophrenia; 4. evidence of mental retardation (IQ \< 70) as determined by the Weschler Abbreviated Scale of Intelligence (WASI; Psychological Corporation, 1999); 5. comorbid neurologic diseases such as seizure disorder; 6. Drug or alcohol abuse or dependence disorders in the 4 months prior to study recruitment, although a lifetime history of substance or alcohol disorders can be present if the child has been abstinent for at least 6 months (see further discussion below); 7. evidence of an unstable medical or psychiatric disorder that requires immediate hospitalization or other emergency medical treatment; 8. a positive pregnancy test; participants will be encouraged but not mandated to discuss a positive pregnancy test with their guardians and we will follow local laws. 9. any contraindication for MRI, including metal in the body related to an injury or surgery (e.g., surgical clips, metal fragments in the eyes), piercings that cannot be removed, braces, or permanent retainers.
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'TRIPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR']}}, 'enrollmentInfo': {'count': 214, 'type': 'ACTUAL'}}
Updated at
2024-02-26

1 organization

1 product

3 indications

Indication
Anxiety